BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.59 USD | -0.51% |
|
+2.31% | -12.27% |
| Jul. 01 | BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) dropped from Russell 3000E Growth Index | CI |
| Jul. 01 | BioMarin Pharmaceutical Inc.(NasdaqGS:BMRN) added to Russell 1000 Defensive Index | CI |
Presenter SpeechCory Kasimov (Analysts)Okay. Good morning, everyone. From the virtual JPMorgan...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
84.59
USD
Average target price
109.4
USD
Spread / Average Target
+29.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.27% | 16.06B | |
| +7.40% | 101B | |
| +7.76% | 42.18B | |
| -14.37% | 32.26B | |
| +82.32% | 29.79B | |
| +2.33% | 14.45B | |
| -8.56% | 12.01B | |
| +182.74% | 10.71B | |
| +3.67% | 8.89B | |
| -56.23% | 8.83B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- Transcript : BioMarin Pharmaceutical Inc. Presents at 39th Annual JPMorgan Virtual Healthcare Conference, Jan-11-2021 08
